Previously, we designed a third-generation CAR targeting CD19 that employs CD28, 4-1BB, and CD3ζ, similar to the framework of CAR-T cells, and showed that such a construct was feasible to generate CAR-NK-92 cells with high and selective cytotoxicity against CD19-positive tumor cells [15]. This evidence concerns the gene CD19 and neoplasm.